Long‐term safety of vedolizumab for inflammatory bowel disease

BACKGROUND: Vedolizumab, a gut‐selective α(4)β(7) integrin antibody, is approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). AIM: To report the final results from the vedolizumab GEMINI long‐term safety (LTS) study. METHODS: The phase 3, open‐label GEMINI...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Aliment Pharmacol Ther
Päätekijät: Loftus, Edward V., Feagan, Brian G., Panaccione, Remo, Colombel, Jean‐Frédéric, Sandborn, William J., Sands, Bruce E., Danese, Silvio, D’Haens, Geert, Rubin, David T., Shafran, Ira, Parfionovas, Andrejus, Rogers, Raquel, Lirio, Richard A., Vermeire, Séverine
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Efficacy and Safety of Biologics for Crohn's Disease
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540482/
https://ncbi.nlm.nih.gov/pubmed/32876349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.16060
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia